11:59 AM EST - Marvel Biosciences Corp : With its wholly owned subsidiary, Marvel Biotechnology Inc., announced today that in a pre-clinical mouse study conducted by the Company, its lead drug candidate MB-204 successfully entered the brain and occupied its target, the adenosine A2a receptor. The adenosine A2a receptor has been validated by numerous scientific studies that it plays a significant role in various pathologies such as Alzheimer's Disease and depression. Marvel Biosciences Corp
shares V.MRVL are trading unchanged at $0.10.
